Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial.
Saved in:
| Title: | Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial. |
|---|---|
| Authors: | Daley-Yates P; Respiratory Clinical Development, GSK Research and Development, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex, UB11 1BT, UK. Peter.T.Daley-Yates@gsk.com., Keppler B; Metabolon Inc., 617 Davis Drive, Suite 100, Morrisville, NC, 27560, USA., Baines A; Medicines Development Centre, GSK Research and Development, Stevenage, UK., Bardsley G; Tauranga Hospital, 829 Cameron Road, Tauranga South, Tauranga, 3112, New Zealand., Fingleton J; Medical Research Institute of New Zealand, Wellington, New Zealand. |
| Source: | Respiratory research [Respir Res] 2022 Sep 20; Vol. 23 (1), pp. 258. Date of Electronic Publication: 2022 Sep 20. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1465-993X |
|---|---|
| DOI: | 10.1186/s12931-022-02164-w |
